Alteplase (Activase)
A clot-dissolving medicine given into a vein. It binds to the fibrin in a blood clot and starts to break the clot down. The US label for Activase lists three uses: acute ischemic stroke, acute heart attack, and acute massive pulmonary embolism, which means blood clots that block blood flow in the lungs.
Also called Activase · tPA · Tissue plasminogen activator
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 8410. US application BLA103172. The label record read here is effective 2026-01-20. The openFDA application record lists the original approval as submission ORIG-1 on 13 November 1987 and also covers CATHFLO ACTIVASE, a separate product that is not described here. The label also tells prescribers to rule out bleeding in the brain as the cause of stroke symptoms before treatment and gives a time limit from symptom onset; this page does not reproduce those details. This is a regulatory record, not a finding about how well the medicine works.
Trials at a glance
The figures count the 14 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 14
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Not yet recruiting | Active, not recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 2 | 0 | 2 |
| Phase 3 | 1 | 1 | 7 | 0 | 9 |
| Phase 4 | 0 | 0 | 2 | 1 | 3 |
| All phases | 1 | 1 | 11 | 1 | 14 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Binds fibrin in a blood clot and converts the plasminogen trapped there to plasmin, which starts local breakdown of the clot (US drug label)
Claims and evidence
Context United States label record for Activase (alteplase), application BLA103172
- Recipient
- Recipient not specified
- Population
- People treated for acute ischemic stroke, acute myocardial infarction or acute massive pulmonary embolism, as the label record words its three indications. The label record gives no age range in the indication text read here.
- Care setting
- Not stated in the label record indication text
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label record indication text
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory label)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The US Food and Drug Administration label record for Activase (alteplase), application BLA103172, fetched on 2026-10-30, lists three indications: treating acute ischemic stroke, treating acute myocardial infarction to reduce mortality and the incidence of heart failure, and lysis of acute massive pulmonary embolism. The openFDA application record lists the original submission as ORIG-1, approved on 13 November 1987 and classified Type 1 - New Molecular Entity with priority review, and names GENENTECH as the sponsor.
Applies to Recipient not specified United States label record for Activase (alteplase), application BLA103172
- Certainty method
- Not assessed
- Limitations
- A label list and an approval are regulatory facts, not findings about how well the medicine works for any person. The label text changes over time; this is the record as fetched on 2026-10-30, and the openFDA application record carries no indication text for the 1987 original approval, so the claim does not say what the medicine was first approved to treat. The stroke indication on the label record also carries a requirement to exclude intracranial hemorrhage first and a time limit from symptom onset, which this claim does not restate. The heart attack indication also carries a limitation of use on the label (the risk of stroke may outweigh the benefit in patients at low risk of death or heart failure), which this claim does not restate either. The same application also covers CATHFLO ACTIVASE, a separate product, which this claim does not cover. openFDA says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (10)
-
Supports openFDA drug label record for ACTIVASE (alteplase): indications and usage, clinical pharmacology
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The three indications on the label record.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
00423e9f1f06dcd6be54cdfa96cdcb4596a11109bf616e4234701a6a11f8d512- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short sentences are quoted. The raw record is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.
-
Supports openFDA drug label record for ACTIVASE (alteplase): indications and usage, clinical pharmacology
- Locator
- results[0].openfda.application_number[0]
- How it applies
- The application number on the label record.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
00423e9f1f06dcd6be54cdfa96cdcb4596a11109bf616e4234701a6a11f8d512- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short sentences are quoted. The raw record is committed in the atlas repository. A second copy was fetched 2026-11-09; its bytes differ from the 2026-10-30 copy. The 2026-11-09 copy is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].application_number
- How it applies
- The application number of the openFDA application record.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].submissions[7].submission_type
- How it applies
- The original submission (ORIG, number 1).
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].submissions[7].submission_status_date
- How it applies
- The date of the original approval, written as eight digits (year, month, day).
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].submissions[7].submission_class_code_description
- How it applies
- The submission classification of the original approval.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].submissions[7].review_priority
- How it applies
- The review priority of the original approval.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].sponsor_name
- How it applies
- The application sponsor, as the record writes the name.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].products[0].brand_name
- How it applies
- The brand name of the first listed product.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for BLA103172: ACTIVASE and CATHFLO ACTIVASE (alteplase)
- Locator
- results[0].products[1].brand_name
- How it applies
- The application also lists CATHFLO ACTIVASE, a separate product.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
a39f161583a9ec7817df523732f44e369854b1335e975d683176dea0a65f519f- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 14
Record details
- Record id
cardio:alteplase- Content hash
970a7d99134e2c3ec1d40a12361425903ed4c3c88e563c9b8bc4e5e1b2a6a29e